Loading...
XSHE
300642
Market cap433mUSD
Dec 05, Last price  
18.91CNY
1D
2.05%
1Q
-30.27%
IPO
-10.71%
Name

Tellgen Corp

Chart & Performance

D1W1MN
XSHE:300642 chart
P/E
88.76
P/S
7.02
EPS
0.21
Div Yield, %
0.79%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
-0.21%
Revenues
437m
-19.53%
48,710,54076,828,379118,200,965169,382,003231,217,644302,888,219364,846,388441,452,526489,580,919654,588,606715,970,892542,809,310436,781,000
Net income
35m
-61.37%
13,618,10922,576,48036,003,23665,778,55397,765,499126,814,971141,690,851157,018,318120,552,785161,082,764124,757,66689,403,54234,535,000
CFO
165m
+15.90%
6,850,50026,329,10040,808,99864,668,23198,421,152105,997,332161,317,879174,843,00796,833,97182,613,509164,719,466142,045,487164,624,000
Dividend
May 23, 20240.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. It offers tumor markers, human papilloma virus test kits, ToRCH products, Y chromosome microdeletions test kits, and multiplex immunoassay systems. The company was founded in 2003 and is based in Shanghai, China.
IPO date
Apr 21, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT